MetaCap

Assembly Biosciences (ASMB) vs Evotec (EVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Assembly Biosciences (ASMB) has outperformed Evotec (EVO) over the past year, losing 42.4% versus a loss of 55.6%. Over five years, ASMB leads with a -21.3% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $454.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%EVO-55.56%
+35%-13%-60%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%EVO-94.42%
+46%-27%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus EVO key metrics
MetricASMBEVO
Share price$22.19$1.32
Market cap$454.39M$469.11M
1-day change-1.38%-8.97%
YTD return-34.75%-57.14%
1-year return-42.36%-55.56%
5-year return-21.31%-94.44%
P/E ratio (TTM)29.59—
EPS (TTM)$0.75$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M—
Revenue growth (YoY)+153.52%—
Net income (latest FY)$-6.12M—
Operating margin-16.76%—
Net margin-8.47%—
52-week high$39.65$3.87
52-week low$19.20$1.32
Distance from 52-week high-44.04%-65.89%
Analyst consensusstrong_buybuy
Avg. price target upside+130.73%+237.12%
Average volume309.38K109.16K
Shares outstanding20.48M355.39M
Employees734,379
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ASMB has outperformed EVO by 13.2 percentage points over the past year.

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

ASMB vs EVO FAQ

Which is bigger, Assembly Biosciences or Evotec?

Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $454.39M for Assembly Biosciences (ASMB).

Which stock has performed better over the past year, ASMB or EVO?

ASMB returned -42.36% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.

Are Assembly Biosciences and Evotec in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons